Medplus Health Services Other Announcement

Medplus Health Services Earnings Call Transcript: Key Takeaways

Medplus reported Q2 revenue of ₹2,037.1 Cr with 21.3% pharmacy growth, but EBITDA margins were hit by state-mandated wage hikes.

Call

Guides 10% growth

Medplus Health Services Share Pledge

Catalyst Trusteeship pledged 34,00,000 Medplus Health Services shares (2.83%) as debenture collateral. Total encumbered shares rose to 2,41,50,400 (20.10% of capital).

Medplus Health Services Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹2,037cr (+21.3% YoY), operating EBITDA ₹98cr (4.8% margin), reported PAT ₹56cr (+1% YoY). Store expansion continues; no explicit guidance given.

Medplus Health Services Employee Stock Options

MedPlus allotted 19,095 equity shares to employees on exercise of ESOP 2021 options. Paid-up capital rises to Rs 24.03 Crore.

Medplus Health Services Q2 FY27 Results: Net Profit ₹56.1 Cr, Up 1.1% YoY

Medplus Health Services Ltd reported revenue from operations of ₹2,037 Cr (+21.3% YoY) and net profit of ₹56.1 Cr (+1.1% YoY) for Q2 FY27.

Key figure

Net profit ₹56.1 Cr · +1.1% YoY

Medplus Health Services Adverse Business Impact

Optival Health, a MedPlus subsidiary, had drug licences suspended at five Karnataka stores for 1–7 days. Expected impact is about Rs 8.66 lakhs.

Value

₹0.09 Cr

Execution

1 to 7 days per store

Mahindra & Mahindra Financial Services Other Announcement

Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.

ACME Solar Holdings Other Announcement

ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.

eMudhra Other Announcement

eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.

Aarti Pharmalabs Other Announcement

Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.

Sagarsoft (India) Other Announcement

Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.

Sadhana Nitro Chem Other Announcement

Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.